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Using a speciﬁc enzyme-linked immunosorbent assay, IL-10 concentrations were measured in serum from 62 patients with ulcera-
tivecolitis(UC),43withCrohn’sdisease(CD),25withothercolitides,and44normalcontrolsubjects.SerumIL-10concentrations
were increased in patients with active UC but not in those with active CD when compared with normal control subjects. A time
course study showed that in patients with UC and CD, serum concentrations of IL-6 and C-reactive protein increased during the
acute phase and returned to normal as patients go into remission. Notably, serum IL-10 concentrations increased during the phase
of disease resolution and declined thereafter regardless of the treatment modality. Gel ﬁltration analysis indicated that IL-10 circu-
lated predominantly as a dimer. In conclusion, this study shows that serum IL-10 is increased during disease recovery in patients
with inﬂammatory bowel disease, and may be a helpful marker in monitoring disease status.
Copyright © 2006 Keiichi Mitsuyama et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Thecauseofulcerativecolitis(UC)andCrohn’sdisease(CD)
isunclear.Itremainstobedeterminedwhetherthesediseases
represent an abnormal response to normal antigenic stimuli
or an appropriate response to persistently abnormal stimuli
[1, 2]. However, it is now well accepted that several cytokines
with proinﬂammatory activities, including interleukin (IL)-
1, IL-6, IL-8, IL-12, and tumor necrosis factor (TNF)-α,a r e
upregulated in inﬂammatory bowel disease (IBD) and play a
key role in the clinical and immunopathological manifesta-
tions of the disease [3–6].
IL-10 is an immunoregulatory cytokine that strongly
downregulates the production of proinﬂammatory cytokines
andThelper1cytokines[7–12].Ofparticularinterestarethe
data on IL-10 deﬁcient mice by Kuhn et al, showing chronic
noninfectiousintestinalinﬂammation[13].Thisﬁndingcor-
roborates the action of IL-10 against chronic stimulation of
the intestinal immune system. It has also been demonstrated
that an elevated production of proinﬂammatory cytokines
by IBD mononuclear cells could be downregulated in vitro
by external IL-10, and also in vivo with topical IL-10 enema
preparations [14]. This indicates that the intrinsic intestinal
bioactivity of IL-10 may be insuﬃcient to control intestinal
inﬂammation. Therefore, recognition of this cytokine will
provide a new dimension to understanding the pathophys-
iology of IBD.
In the present study, we identiﬁed and quantitated the
serum IL-10 in patients with IBD using a speciﬁc and sen-
sitive enzyme-linked immunosorbent assay (ELISA) and ex-
amined the relationship of serum IL-10 to the proinﬂamma-
tory cytokine IL-6 and other clinical parameters.
MATERIALS AND METHODS
Patientsandcontrolsubjects
Blood samples were collected from 62 patients with UC (me-
dian age: 33.9 years; 37 male, 25 females) and 43 with CD
( m e d i a na g e :2 9 . 4y e a r s ;2 9m a l e s ,1 4f e m a l e s )d e ﬁ n e da c -
cording to the characteristic clinical, endoscopic, radiologic,
and histologic criteria. The severity of active UC was speci-
ﬁed according to the criteria of Truelove and Witts as mild,
moderate, or severe [15]. Only those patients who were clas-
siﬁed as fully in remission were regarded as having inac-
tive UC. Disease activity of CD was assessed according to2 Mediators of Inﬂammation
scores established by the International Organization for the
Study of Inﬂammatory Bowel Disease (IOIBD). A score of 0
to 1 was considered to be inactive disease, whereas a score
of 2 or greater was classiﬁed as active disease [16]. Previ-
ous work has shown a signiﬁcant correlation between the
IOIBD score and the Crohn’s disease activity index (CDAI)
[17]. In terms of disease distribution of UC, 45 patients had
pancolitis, 10 had left colon involvement, and seven had dis-
ease limited to the distal colon. In the CD group, 26 pa-
tients had disease that aﬀected both the ileum and colon, 11
had disease that aﬀected the colon, and six had disease that
aﬀected the ileum. The patients were receiving the follow-
ing treatments at the time of study: oral prednisolone only,
UC = 2, CD = 2; 5-aminosalicylate only, UC = 18, CD =
16; both prednisolone and 5-aminosalicylate, UC = 17, CD
= 10; and no speciﬁc treatment, UC = 25, CD = 18. Sam-
ples were also obtained from 25 patients with other forms of
intestinal inﬂammation, including 20 with infectious colitis
andﬁvewithischemiccolitis,andfrom44healthyvolunteers
of similar age range and sex distribution as the IBD patients.
Informed consent was given by every participant. The study
protocol conformed to the Declaration of Helsinki and was
approved by the local medical ethics committee.
IL-10ELISA
An ELISA sensitive for IL-10 was developed by modifying a
procedure based on the general principles for luminescence
sandwich ELISA (Sumitomo Metal Bio-Science, Inc, Kana-
gawa, Japan) [18]. To brieﬂy summarize the procedure, 96-
well microtiter plates (Microlite 2, Dynatech Laboratories
Inc, Chantilly, Va, USA) were coated overnight at 4◦Cw i t h
100μL/well of the anti-IL-10 monoclonal antibody JES9D7
[19] (ﬁnal concentration, 1μg / m L ;B DP h a r M i n g e n ,S a n
Diego, Calif, USA). Plates were washed with 0.05% Tween
20/Tris-buﬀered saline. The plates were blocked with 250μL
of 1% bovine serum albumin/Tris-buﬀered saline at room
temperature for 2 hours and then were washed. One hun-
dred microliters of sample and 50μLo f0 .05% Tween 20/1%
bovine serum albumin/Tris-buﬀered saline were added to
each well and incubated overnight at 4◦C, and a standard
for IL-10 was run concurrently. Plates were washed, and
100μLofbiotinylatedanti-IL-10monoclonalantibodyJES3-
12G8 [19] (ﬁnal concentration, 1μg/mL; BD PharMingen)
w a sa d d e dt oe a c hw e l la n di n c u b a t e df o r2h o u r sa tr o o m
temperature. Plates were then washed and incubated with
streptavidin/alkaline phosphatase conjugate (Bethesda Re-
search Laboratories, Gaithersburg, Md, USA) at a dilution of
1 : 6000 for 30 minutes at room temperature. After washing
again, LUMI-PHOS (Lumigen, Inc, Detroit, Mich, USA) was
addedtoeachwell.Luminescenceintensitywasmeasuredus-
ing a luminescence reader (MLR100, Corona Electric, Tokyo,
Japan). The sensitivity of this ELISA was 1.0pg/mL. Coef-
ﬁcients of variation for intraassay and interassay replicates
werelessthan5.8%and8.1%,respectively.RecoveryofIL-10
from serum was 100.0±12.9% (mean ± SD). Detectable lev-
els of IL-10 that always followed the standard curve were de-
termined by sample titration. The results of this IL-10 assay
correlated strongly with those determined using a previously
established ELISA [19] (DNAX Research Institute, Palo Alto,
Calif, USA) (n = 20, r = 0.9729, P<. 0001) and a commer-
cially available ELISA kit (Biosource International, Camar-
illo, Calif, USA) (n = 42, r = 0.9874, P<. 0001).
DeterminationofIL-6andotherlaboratoryparameters
Serum concentrations of IL-6 were measured using ELISA
(SRLInc,Tokyo,Japan)aspreviouslydescribed[20–22].The
lower limit of detection for IL-6 was 4.0pg/mL. Assay of C-
reactive protein (CRP)wasperformedusing lasernephelom-
etry (normal range, < 350ng/mL) (Hoechst Japan, Tokyo,
Japan). Total leukocyte counts, hemoglobin concentrations,
plateletcounts,anderythrocytesedimentationrateswerede-
termined using standard procedures.
Gelﬁltrationanalysis
Chromatographic procedures were performed using a fast
protein liquid chromatography (FPLC) system (Pharmacia,
Sollentuna, Sweden). Serum sample or recombinant human
IL-10 was fractionated by gel ﬁltration through a Superose
12 HR 10/30 column equilibrated with 50mM phosphate
buﬀer, pH 7.2, and 150mM NaCl. Each sample (20μL) was
eluted with buﬀer at the rate of 0.4mL/min. Fractions of
0.5mL were collected, and immunoreactive IL-10 levels in
each fraction were measured using ELISA. The column was
calibrated with marker proteins of known molecular weight.
Statistics
Data were analyzed using the Mann-Whitney U test and the
Spearman rank correlation coeﬃcient. Diﬀerences were con-
sidered signiﬁcant at P<.05.
RESULTS
Figure 1 shows serum concentrations of CRP, IL-6, and IL-
10 in 62 patients with UC, 43 patients with CD, 25 pa-
tients with other colitides, and 44 normal control subjects.
As shown in Figures 1(a) and 1(b), serum concentrations
of CRP and IL-6 were increased in patients with active UC
(CRP, P<. 0001; IL-6, P<. 0001) and active CD (CRP,
P<. 0001; IL-6, P<. 0001) compared with normal con-
trol subjects. Patients with active disease had a higher con-
centration of CRP (UC, P = .0004; CD, P<. 0001) and
IL-6 (UC, P<. 0001; CD, P<. 0001) than those with inac-
tive disease. In patients with active disease, CRP concentra-
tions were higher in patients with CD than in those with UC
(P<. 0038), whereas IL-6 concentrations were comparable
between UC and CD (P = .0973). As shown in Figure 1(c),
serum IL-10 concentrations were increased in those with ac-
tive UC (P = .0086) but not with active CD (P = .07663)
when compared with normal control subjects; the concen-
trations were higher in patients with active UC than withKeiichi Mitsuyama et al 3
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Figure 1: Serum concentrations of CRP (a), IL-6 (b), and IL-10 (c) in patients with ulcerative colitis (UC), Crohn’s disease (CD), other
colitides and normal control subjects. The bars indicate the median ±25 percentile. The lower bar indicates the 10th percentile, and the
upper bar the 90th percentile. ns: not signiﬁcant, n: number of patients. Concentrations of CRP are shown on a logarithmic scale (vertical
axis).
active CD (P = .0338). No statistical association was ob-
served between the concentration of IL-10 and clinical dis-
ease severity andactivity or laboratory parameters, including
serum IL-6, CRP, erythrocyte sedimentation rates, or total
leukocyte counts (data not shown). Also, there were no sig-
niﬁcant diﬀerences in IL-10 concentrations between patients
with and without steroid therapy regardless of the disease ac-
tivity (data not shown).4 Mediators of Inﬂammation
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Figure 2: Time course of serum CRP, IL-6, and IL-10 concentrations in three patients with ulcerative colitis (UC) ((a)–(c)) and two with
Crohn’s disease (CD) ((d), (e)). (a) A 17-year-old woman with UC who had total colonic involvement receiving total parenteral nutrition.
(b) A 17-year-old man with UC who had total colonic involvement treated with both 5-aminosalicylate and prednisolone (40–20mg daily).
(c) A 24-year-old man with UC who had total colonic involvement treated with prednisolone (40–15mg daily). (d) A 21-year-old man
with CD who had colonic involvement treated with 5-aminosalicylate. (e) A 36-year-old woman with CD who had ileocolitis and received
nutrition therapy only. 5ASA: 5-aminosalicylate; PSL: prednisolone.
Figure 2showsthetimecourseofserumIL-10andproin-
ﬂammatory parameters, CRP and IL-6, followed longitudi-
nally in three patients with UC and two patients with CD.
Eventually, disease activity in all ﬁve patients was controlled
by the treatment. In these cases, serum concentrations of
IL-6 and CRP increased during the acute phase and re-
turned to normal as patients went into remission. It should
be noted that increased concentrations of IL-10 were consis-
tently found as the disease began to resolve regardless of the
treatment modality, and declined thereafter when the disease
achieved stable remission.
TherepresentativeelutionproﬁlesofIL-10immunoreac-
tivities in sera from patients with IBD are shown in Figure 3.
A substantial proportion of serum IL-10 is eluted in the sim-
ilar fractions regardless of the disease activity. Sizing with
molecular mass standards revealed the largest peak to be ap-
proximately 45kDa, consistent with the predicted molecular
mass for a recombinant human IL-10 dimer. Also, there were
additional small peaks that eluted higher molecular weight
form.
DISCUSSION
Many of the pathologic and clinical features of IBD reﬂect
the eﬀects of key cytokines essential to sustain inﬂammation
[3–5]. In the present investigation, we focused on the levels
of circulating immunoregulatory cytokine IL-10 in patients
with intestinal inﬂammation. There have been some reports
concerning serum IL-10 in patients with IBD. Kucharzik et
al measured serum IL-10 concentrations in 44 patients with
UC, 40 patients with CD, and 30 healthy control subjects.
Increased IL-10 concentrations were seen in patients with
both active UC and active CD compared with healthy con-
trol subjects [23]. Nielsen et al reported that serum IL-10Keiichi Mitsuyama et al 5
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Figure 3: Fractionation of serum by FPLC gel ﬁltration chromatography. A representative elution proﬁle of a patient with ulcerative colitis
(UC) and Crohn’s disease (CD) is presented. Fractions were assayed for IL-10 concentrations by ELISA. The points represent the mean of
duplicate analyses. The elution proﬁles of the molecular markers thyroglobulin (669kDa), ferritin (440kDa), catalase (232kDa), aldlase
(158kDa), BSA (67kDa), ovalbumin (43kDa), chymotrypsinogen A (25kDa), and ribonuclease A (13.7kDa) are indicated by arrow heads.
The single peak corresponding to recombinant human IL-10 is marked by the arrow.
concentrations did not diﬀer among UC (n = 20), CD
(n = 14), and healthy control subjects (n = 22) [24]. Our
large scale study (UC, n = 62; CD, n = 43; healthy control
subjects, n = 44) showed the increase in serum IL-10 in pa-
tients with active UC but not in those with CD, as well as
in patients with other forms of colitis and normal control
subjects. This result is not simply because of lower inﬂam-
matory reaction in our CD population because CRP concen-
trations were higher in patients with CD than in those with
UC.Ourserumdataareinconsistentwithpreviousreportsof
increased tissue levels of IL-10 mRNA exclusively in UC but
notinCD[24].ThediﬀerentproﬁleofIL-10inthesetwodis-
eases reported may result in variable manifestations between
thetwotypesofIBD:activatingsignals,respondingcells,and
related pathogenic events may be diﬀerent in both diseases.
We next compare the serum IL-10 level with clinical
and laboratory parameters of the disease activity during the
course of disease. During the active disease, serum concen-
trations of IL-6 and CRP increased and returned to normal
as patients went into remission, similar to the previous re-
ports [20–22, 25]. Notably, we found a diﬀerent pattern with
serum IL-10: in individual patients with both forms of IBD
it gradually increased with the clinical resolution of disease
but declined thereafter regardless of the treatment modality.
Very similar results have been described with another im-
munoregulatory cytokine—soluble gp130, a soluble compo-
nent of the IL-6 receptor complex—showing a gradual in-
crease in serum concentrations during the recovery phase
rather than the very acute phase in the same diseases [26].
The signiﬁcance of the delayed increase in these cytokines
is unclear. However, it is plausible that this phenomenon
may contribute to the systemic downregulation of the acute
inﬂammatory process. Furthermore, this delayed increase
implies that the contradictoryresults ofserum IL-10concen-
trations in IBD reported previously [23, 24]m a yd e p e n do n
subtle diﬀerences in the phase of disease. We must keep in
mind that the timing of cytokine measurement during the
course of disease is a critical factor detecting the changes in
cytokine levels, especially those with immunoregulatory ac-
tivities. Even though the role of serum IL-10 in IBD is not
fully understood, its serial measurement may help determine
disease prognosis and conﬁrm treatment eﬃcacy.
Glucocorticoid is regarded as one of the powerful phar-
macological modulators of cytokine production [27]. Some-
what surprisingly, we could not ﬁnd statistical diﬀerences
in serum IL-10 concentrations between IBD patients with
and without steroid therapy. A time course of these patients
also showed that ongoing treatment with steroids and 5-
aminosalicylate did not seem to aﬀect serum IL-10 levels. Al-
though it has become clear that glucocorticoids boost IL-10
production in vitro, there is no direct evidence regarding the
in vivo eﬀect of glucocorticoids on the production of IL-10
[27]. However, our data indicate that serum IL-10 level may
reﬂect the inﬂammatory response related to the disease itself
rather than the therapeutic eﬀect per se in IBD patients.
Our understanding of the mucosal immune response
in IBD suggests that immunotherapeutic drugs may be de-
signed rationally by targeting speciﬁc steps in the pathway
of immune activation. There is now widespread apprecia-
tion that proinﬂammatory cytokines such as IL-1, IL-6, IL-
8, IL-12, or TNF-α play a predominant role in immune and
inﬂammatory reactions in patients with IBD [3–6]. More-
over, previous data [28, 29] show that the level of IL-1 re-
ceptor antagonist, a natural antagonist of IL-1 [30], is not6 Mediators of Inﬂammation
proportionally increased in IBD mucosa, and this imbalance
of IL-1 and IL-1 receptor antagonist may lead to persistent
inﬂammation. Interestingly, IL-10 has the capacity to inhibit
proinﬂammatory cytokines while stimulating IL-1 receptor
antagonist in vitro [8]. These data support the belief that
IL-10 and related molecules may be therapeutic. Although
a preliminary study of IL-10 in patients with active CD sug-
gested beneﬁt [31], subsequent trials failed to demonstrate
eﬃcacy [32, 33]. Recently, novel alternative therapeutic ap-
proaches, including the use of genetically modiﬁed Lactococ-
cus lactis, gelatine microspheres containing IL-10, adenoviral
vectors encoding IL-10, and combining regulatory T cells,
have caused a signiﬁcant reduction in intestinal inﬂamma-
tion in diﬀerent mouse models [34], and they might be use-
ful for treatment of human IBD.
Next we observed the elution proﬁle of serum IL-10 by
gel ﬁltration to elucidate the structure of its circulating form.
We found that serum IL-10 may exist predominantly as a
dimer regardless of the disease status. Thus, circulating IL-
10 may be biologically active because this form of IL-10 can
bind speciﬁcally to its receptor [35]. There is also a small
amount of higher molecular weight form of circulating IL-
10, most likely representing an aggregated form or a complex
with other molecules, similar to what has been described for
other cytokines [22, 26]. To our knowledge, the present re-
port is the ﬁrst demonstration of the molecular weight and
form of circulating IL-10 in patients with IBD.
In conclusion, the present study shows that serum IL-10
isincreasedduringdiseaserecoveryinpatientswithIBD,and
could be a valuable marker in monitoring disease status.
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